European Society of Cardiology
European Society of Cardiology
September 03, 2019
6 min watch

VIDEO: Large, real-world analysis provides new insights on apixaban for nonvalvular AF

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PARIS — In this video exclusive, P. Gabriel Steg, MD, FESC, provides investigator insight on NAXOS, the largest real-world analysis on the effectiveness and safety of apixaban compared with a vitamin K antagonist in Europe among patients with nonvalvular atrial fibrillation.

The NAXOS analysis included nearly the entire French population with nonvalvular AF, Steg, director of the coronary care unit in the cardiology department at Hôpital Bichat and professor of cardiology at the Université Paris – Diderot, told Cardiology Today.

According to data presented at the European Society of Cardiology Congress, apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was associated with a lower rate of major bleeding, stroke and systemic thrombotic events.

Watch the video for more.